Martínez PC, Vargas IB, Silva H

Language: Spanish
References: 21
Page: 228-233
PDF size: 91.26 Kb.

ABSTRACT

Introduction. Due the high prevalence of the detrusor overactivity and its expensive treatment, 1 the attention is focusing in the cases resistant to treatment. From the first report of administration of botulinum toxin-A in neurogenic bladder, its use is multiply faster to more urinary pathologies regarding the storage mechanism.
Objectives. To know the status of the mechanism of action and uses of botulinum toxin-A in different pathologies of the lower urinary tract, doses and administration ways.
Material and methods. A literature review.
Results. The understanding of lower urinary tract physiology and physiopathology has advanced notably in latest years. Specially regarding to the urothelium that works as a pressure sensing organ, it takes charge of the signal transduction that modulate de micturion reflex, also the afferent feedback from lower urinary tract.2 Actually, botulinum toxin-A is used on detrusor overactivity (with or without neurological basis), pelvic floor inestability and pelvic chronic pain syndrome, detrusor sphincter dysynergia (neurogenic or no neurogenic) and prostate hyperplasia.
Conclusion. The incomplete success in the treatment of detrusor overactivity focused in the efferent component has redirected the attention in the afferent mechanism1,2,10 of the bladder storage disorders. Today botulinum toxin-A is widespread used in detrusor overactivity, pelvic floor instability and pelvic chronic pain syndrome, detrusor sphincter dysynergia and prostate hyperplasia. Also the limit for future applications is only the clinicians and researchers imagination.

REFERENCES

1. Sahai A, Khan M, Fowler CJ, Dasgupta P. Botulinum Toxin for the Treatment of Loger Urinary Tract Symptoms: A Review. Neurourol Urodyn 2005;24:2-12.

2. Chapple C, Patel A. Botulinum Toxin- New Mechanisms, New Therapeutic Directions? Eur Uro 2006;49:606-8.

3. Schurch B, Stöhrer M, Kramer G, Schmid DM, Gaul G, Sauri D. Botulinum-A Toxin for treating detrusor Hyperreflexia in spinal cord injuried patients: A new alternative to anticholinergic drugs? Preliminary Results. J Urol 2000;164:692-7.

4. Schurch B, Schmid DM, Stöhrer M. Treatment of neurogenic incontinente with Botulinum Toxin-A. ��N Engl J Med 2000;342:665.

5. Hetrick DC, Glazer H, Liu YW, Turner JA, Frest M, Berger RE. Pelvic Floor Electromyography in Men With Chronic Pelvic Pain Syndrome: A Case-Control Study. Neurourol Urodyn 2006;25:46-9.

6. Abrams P, Hanno P, Wein A. Overactive Bladder and Painful Bladder Syndrome: There need not be confusion. Neurourol Urodyn 2005;24:149-50.

7. Shin SM, Park DS. Multiregional Injections of Low Dose Botulinum Toxin A fro Men with Chronic Pelvis Pain Syndrome. J Urol 2006;175:34(Abstract 104).

8. Schurch B, Reitz A. Botox in Urology: A new treatment Modality without Limitations? EAU Update Series 2004;2:170-8.

9. Madersbacher H, Bemelmans B. Neurogenic voiding dysfunction. ESU Course 18, 14 March 2003. Madrid, Spain.

10. Schurch B, Sauri D, Rodic B, Curt A, Meyer M, Dossier AB. Botulinum-A Toxin as a Treatment of Detrusor- Sphincter Dyssynergia: A Prospective Study in 24 Spinal Cord Injury Ptients. J Urol 1996;155:1023-9.

11. Reitz A, Stöhrer M, Kramer G. European experience of 200 cases treated with botulinum-A toxin injection in to the detrusor muscle for neurogenic incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510-5.

12. Riccabona M, Koen M, Schindler M, Goedele B, Pycha A, Lusuardi L. Botulinum–A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningocele with detrusor hyperreflexia. J Urol 2004;171:845-8.

13. Reitz A , Stöhrer M, Krame G, Del Popolo G, Chartier-Kastler E, et al. European Experience of 200 cases treated with botulinum-a toxin injections into the detrusor muscle for neurogenic incontinence. J.Urol 2003;169:373 (Abstract 1393).

14. Schurch B, de Séze M, Denys P, Chartier-Kastler E, Ismael S, Everaert K, Keppenne V, et al. Botulinum Toxin A (Botox) in neurogenic urinary incontinence: Results from a multicentre randomized, controlled trial. Neurourol Urodyn 2005;23:609-610 (Abstract 151).

15. Apostolidis A, Popat R, Yiangou Y, Dasgupta P, Anand P, Fowler CJ. A possible explanation for the exceptional efficacy of Botulinum Toxin treatment for Detrusor Overactivity. Neurourol Urodyn 2005;23:608-9 (Abstract 150).

16. Apostolidis A, Dasgupta P, Fowler CJ. Proposed Mechanism for the Efficacy of Injected Botulinum Toxin in the Treatment of Human Detrusor Overactivity. Eur Urol 2006;49:644-50.

17. Staehler M D, Sauter T, Miller Kurt. Botulinum Toxin A injection in the M. detrusor vesicae is an alternative to bladder augmentation in children with intolerable detrusor hiperreflexia. J Urol 2003;169:105 (Abstract 409).

18. Schulte-Baukloh H, Schobert J, Stolze T, Stürzebecher B, Weib C, Knispel HH. Efficacy of Botulinum-A Toxin Bladder Injections for the Treatment of Neurogenic Detrusor Overactivity in Multiple Screrosis Patients: An Objective and Subjective Análisis. Neurourol Urodyn 2006;25:110-5.

19. Grosse JO, Kramer G, Löchner-Ernst D, Stöhrer M. Outcome of repeat detrusor injections of botulinuma toxin (BTX-A) for severe neurogenic detrusor overactivity and incontinence. J Urol 2003;169:373 (Abstract 1394).

20. Loch A, Loch T, Osterhage J, Allousi S, Stökle M. Botulinum- A Toxin detrusor injections in the treatment of Non-Neurologic and Neurologic cases of urge incontinence. J Urol 2003;169:125 (Abstract 481).

21. Kessler TM, Danuser H, Schumacher M, Studer UR, Burkhard FC. Botulinum A-Toxin Injections into the detrusor: An effective treatment in idiopathic and neurogenic Detrusor Overactivity? Neurourol Urodyn 2005;24:231-6.